News & Updates
Filter by Specialty:
CV health tool effectively promotes discussions during routine follow-up in cancer survivors
A novel electronic health record (EHR) clinical decision support tool, otherwise called the AH-HA* tool, was effective in promoting cardiovascular health (CVH) discussions among cancer survivors during routine follow-up. This was the primary result of a clinic-randomized, hybrid effectiveness-implementation trial presented at ASCO 2023.
CV health tool effectively promotes discussions during routine follow-up in cancer survivors
06 Jul 2023
Lazertinib improves PFS vs gefitinib in 1L treatment of EGFR-mutated NSCLC
The third-generation EGFR tyrosine kinase inhibitor (TKI) lazertinib significantly improves progression-free survival (PFS) vs gefitinib in first-line (1L) treatment of patients with EGFR -mutated, locally advanced or metastatic non-small-cell lung cancer (NSCLC) harbouring an exon 19 deletion or exon 21 L858R mutation, results of the phase III LASER301 trial have shown.
Lazertinib improves PFS vs gefitinib in 1L treatment of EGFR-mutated NSCLC
06 Jul 2023
More evidence for COVID-19 vaccine safety in kids
COVID-19 vaccines can be safely administered in children, with a recent study showing that out of the numerous health outcomes monitored in near real time, the safety signal identified was for only myocarditis or pericarditis.
More evidence for COVID-19 vaccine safety in kids
05 Jul 2023
Patient-reported tool helps assess symptoms, vision perception after IOL implantation
Use of the 37-item Assessment of IntraOcular Lens Implant Symptoms (AIOLIS) instrument appears effective in evaluating symptoms and general perceptions of vision associated with cataract surgery and intraocular lens (IOL) implants, reports a study.
Patient-reported tool helps assess symptoms, vision perception after IOL implantation
05 Jul 2023
Dalpiciclib a 1L option for HR-positive, HER2-negative advanced breast cancer regardless of menopausal status
Adding dalpiciclib to an aromatase inhibitor (AI) significantly improves progression-free survival (PFS) vs an AI alone in first-line (1L) treatment of hormone receptor (HR)–positive, HER2-negative advanced breast cancer regardless of patients’ menopausal status, a phase III trial in 42 hospitals in China has shown.